乳腺癌跳跃转移:发生率、相关肿瘤特征及分期淋巴结超声在检测中的作用
本回顾性研究纳入1300例新诊断未治疗的浸润性乳腺癌,评估分期淋巴结超声联合细针穿刺的诊断效能及跳跃转移的发生率与相关肿瘤特征。超声联合FNA敏感度86.0%、特异度100.0%,跳跃转移占全部浸润性癌2.6%、占转移性癌7.2%,跳跃转移与小叶癌及混合导管小叶癌组织学类型相关。
要点
- 分期淋巴结超声联合FNA诊断转移的敏感度86.0%、特异度100.0%、准确率93.6%。
- 跳跃转移占全部浸润性癌2.6%(95%CI 1.8-3.6%),占超声及FNA检出转移性癌7.2%(95%CI 5.1-9.9%)。
- 跳跃转移部位包括腋窝III级、锁骨上淋巴结区、对侧腋窝及远处器官。
关键影像表现/征象
- 跳跃转移定义为跨越不连续淋巴结分期的播散,或无同侧淋巴结转移情况下的远处转移。
- 跳跃转移部位包括腋窝III级4例、锁骨上淋巴结区21例、对侧腋窝2例及远处器官7例。
诊断标准与关键数值
- 超声联合FNA诊断转移的敏感度86.0%、特异度100.0%、阳性预测值100.0%、阴性预测值89.5%、准确率93.6%。
- 跳跃转移占全部浸润性癌2.6%(34/1300,95%CI 1.8-3.6%),占超声及FNA检出转移性癌7.2%(34/470,95%CI 5.1-9.9%)。
- 伴跳跃转移癌与不伴跳跃转移癌相比,小叶组织学比例23.5% vs 6.7%、混合导管和小叶组织学比例11.8% vs 6.7%(p=.005)。
- 跳跃转移与分级、T分期或分子亚型无关联(p>.05)。
临床应用与阅片要点
- 分期淋巴结超声应评估同侧区域淋巴结 basins 包括腋窝III级、锁骨上区及对侧腋窝,以检出跳跃转移。
- 超声可疑淋巴结行FNA活检,FNA良性且超声无可疑淋巴结者行前哨淋巴结活检。
- 小叶癌或混合导管小叶癌患者跳跃转移风险较高,阅片时需注意评估标准清扫范围以外的淋巴结区域。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Staging nodal ultrasound (US) evaluates locations beyond those assessed during routine surgical dissection and has an increasing role in breast cancer management given the growing use of neoadjuvant systemic therapy before surgical staging. OBJECTIVE. The purpose of this study is to identify the patterns of nodal spread of breast cancer observed at staging nodal US and to determine the frequency of skip metastases and associated tumor characteristics. METHODS. This retrospective study included 1269 consecutive patients (31 with bilateral synchronous cancers) who had 1300 newly diagnosed, untreated, invasive breast cancers and underwent US examination of the ipsilateral regional nodal basins from January 2016 through March 2017. Cases with suspicious nodes on US underwent fine-needle aspiration (FNA) biopsy. Cases with benign results on FNA and no suspicious nodes on US underwent sentinel lymph node biopsy. Results of US with FNA were compared with final surgical pathology. Skip metastases were defined as spread across discontiguous nodal levels or distant metastases in the absence of ipsilateral nodal metastases. The incidence and patterns of spread of skip metastases were summarized; associations with tumor characteristics were tested using the Fisher exact test. RESULTS. A total of 591 metastatic cases (45.5%) were confirmed by needle biopsy or sentinel lymph node biopsy, comprising 463 nodal metastases (N+) confirmed by FNA, 121 nodal metastases (N+) confirmed by sentinel lymph node biopsy, and seven distant organ metastases without nodal metastases (N0M1) confirmed by CT-guided biopsy. US with FNA had sensitivity of 86.0%, specificity of 100.0%, PPV of 100.0%, NPV of 89.5%, and accuracy of 93.6%. There were 34 skip metastases, for an incidence of 2.6% (34/1300) (95% CI, 1.8-3.6%) among all invasive cancers and 7.2% (34/470) (95% CI, 5.1-9.9%) among metastatic cancers detected by US and FNA. Skip metastases occurred to axillary level III (n = 4), the supraclavicular nodal basin (n = 21), the contralateral axilla (n = 2), and distant organs (n = 7). Cancers with skip metastases, compared with those with nonskip metastases, had higher rates (p = .005) of lobular histology (23.5% vs 6.7%) and mixed ductal and lobular histology (11.8% vs 6.7%). Skip metastases were not associated with grade, T category, or molecular subtype (p > .05). CONCLUSION. Skip metastases to locations beyond standard surgical axillary dissection occur in 7.2% of metastatic breast cancers. CLINICAL IMPACT. Staging nodal US identifies skip metastases that otherwise would be undetected, helping to achieve more accurate staging and minimize undertreatment.
引用
- Chung HL, Sun J, Leung JWT, et al. Breast Cancer Skip Metastases: Frequency, Associated Tumor Characteristics, and Role of Staging Nodal Ultrasound in Detection. AJR Am J Roentgenol. 2020. PMID: 32997506. doi:10.2214/AJR.20.24371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。